191 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
7 Dec 23
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
8:41am
studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure
424B5
trhi y8g1n67
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-99.1
rw2z2
24 Jul 23
Regulation FD Disclosure
4:04pm
424B5
mj8 4t28ef58p
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.1
bv9i0epf8 cc6k9
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.2
781jdoq432yk7vce
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
s99csnbikmlcq9c
10 May 23
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
5:17pm
8-K
EX-10.1
oxceend dplg
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
DEFA14A
e8f3rzl
22 Jul 22
Additional proxy soliciting materials
9:31pm
8-K
EX-99.1
klp 3dcjoti71e
28 Jun 22
Departure of Directors or Certain Officers
9:46am
DEFA14A
4censqqjspza8t seu8
24 Jun 22
Additional proxy soliciting materials
4:24pm
DEFA14A
syxovm6ai
31 May 22
Additional proxy soliciting materials
4:52pm
8-K
EX-99.2
62f54y8v8r
27 May 22
Regulation FD Disclosure
8:44am